Q2 FY2026 EarningsQ2 FY26 delivered a comprehensive beat against consensus, characterized by record revenue of $37.6M (+99% YoY) vs. $27.1M expected. Diluted GAAP EPS of $0.35 significantly outperformed the $0.11 consensus mean, while Adjusted EBITDA margins reached a robust 43%. Management significantly raised FY26 revenue guidance to >$145M (from >$120M), far exceeding the prior market outlook.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Eton Pharmaceuticals(ETON) the Revenue is 37.59 M (+98.59%), Beat estimate;the EBIT is 12.79 M (+967.4%), Beat estimate;the EPS is 0.35 (+450%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.04B98.59%
0.03B43.27%
+0.01B55.32%
EBITExceed expectations
0.01B967.39%
0.00B389.15%
+0.01B578.24%
EPSExceed expectations
0.35450.00%
0.105205.00%
+0.2450245.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf